These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10219970)

  • 1. Disposition of ropinirole in animals and man.
    Ramji JV; Keogh JP; Blake TJ; Broom C; Chenery RJ; Citerone DR; Lewis VA; Taylor AC; Yeulet SE
    Xenobiotica; 1999 Mar; 29(3):311-25. PubMed ID: 10219970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of ropinirole.
    Kaye CM; Nicholls B
    Clin Pharmacokinet; 2000 Oct; 39(4):243-54. PubMed ID: 11069211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
    Kuzel MD
    Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.
    Thalamas C; Taylor A; Brefel-Courbon C; Eagle S; Fitzpatrick K; Rascol O
    Eur J Clin Pharmacol; 1999 Jun; 55(4):299-303. PubMed ID: 10424323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of SK&F L-190144 in rats and monkeys after oral, intravenous or ocular administration.
    Tang-Liu DD; Richman JB; Lin P; Selim S
    Biopharm Drug Dispos; 1993 May; 14(4):313-24. PubMed ID: 8499582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats.
    Reavill C; Boyfield I; Coldwell M; Nelson P
    J Pharm Pharmacol; 2000 Sep; 52(9):1129-35. PubMed ID: 11045894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.
    Frantz SW; Beskitt JL; Tallant MJ; Zourelias LA; Ballantyne B
    Xenobiotica; 1996 May; 26(5):515-39. PubMed ID: 8736063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist.
    Parker SG; Raval P; Yeulet S; Eden RJ
    Eur J Pharmacol; 1994 Nov; 265(1-2):17-26. PubMed ID: 7883025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man.
    Howell SR; Husbands GE; Scatina JA; Sisenwine SF
    Xenobiotica; 1993 Apr; 23(4):349-59. PubMed ID: 8337893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
    Speed B; Bu HZ; Pool WF; Peng GW; Wu EY; Patyna S; Bello C; Kang P
    Drug Metab Dispos; 2012 Mar; 40(3):539-55. PubMed ID: 22180047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, disposition kinetics, and metabolic pathways of cyclohexene oxide in the male Fischer 344 rat and female B6C3F1 mouse.
    Sauer JM; Bao J; Smith RL; McClure TD; Mayersohn M; Pillai U; Cunningham ML; Sipes IG
    Drug Metab Dispos; 1997 Mar; 25(3):371-8. PubMed ID: 9172957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and disposition of the novel dopamine agonist Z-7760 in rat after intravenous and oral administration.
    Bollard M; Caldwell J; Taylor GW; Strolin-Benedetti M; Semeraro C
    Xenobiotica; 2000 Oct; 30(10):983-91. PubMed ID: 11315106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.
    Siefert HM; Maruhn D; Maul W; Förster D; Ritter W
    Arzneimittelforschung; 1986 Oct; 36(10):1496-502. PubMed ID: 3814211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and metabolism of benoxaprofen in laboratory animals and man.
    Chatfield DH; Green JN
    Xenobiotica; 1978 Mar; 8(3):133-44. PubMed ID: 418580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The disposition and metabolism of meropenem in laboratory animals and man.
    Harrison MP; Moss SR; Featherstone A; Fowkes AG; Sanders AM; Case DE
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():265-77. PubMed ID: 2808212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.
    Walker DK; Ackland MJ; James GC; Muirhead GJ; Rance DJ; Wastall P; Wright PA
    Xenobiotica; 1999 Mar; 29(3):297-310. PubMed ID: 10219969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans.
    Zhu M; Whigan DB; Chang SY; Dockens RC
    Drug Metab Dispos; 2008 Jan; 36(1):24-35. PubMed ID: 17908924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioactivation of eptaloprost in animals and man.
    Hildebrand M
    Prostaglandins; 1993 Aug; 46(2):177-89. PubMed ID: 7692471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.